Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 4
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.
Bartner LR, McGrath S, Rao S, Hyatt LK, Wittenburg LA. Bartner LR, et al. Can J Vet Res. 2018 Jul;82(3):178-183. Can J Vet Res. 2018. PMID: 30026641 Free PMC article. Clinical Trial.
The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. ...Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile....
The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research …
Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.
Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, Brown H, Berthelsen ES, Wakshlag JJ. Gamble LJ, et al. Front Vet Sci. 2018 Jul 23;5:165. doi: 10.3389/fvets.2018.00165. eCollection 2018. Front Vet Sci. 2018. PMID: 30083539 Free PMC article.
Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA). ...Dogs received each of two treatments: CBD oil (2 mg/kg) or placebo oil every 12 h. Each treatment lasted for 4 weeks with a 2-week washout period. ...
Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannab …
Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy.
McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. McGrath S, et al. J Am Vet Med Assoc. 2019 Jun 1;254(11):1301-1308. doi: 10.2460/javma.254.11.1301. J Am Vet Med Assoc. 2019. PMID: 31067185
ANIMALS: 26 client-owned dogs with intractable idiopathic epilepsy. PROCEDURES: Dogs were randomly assigned to a CBD (n = 12) or placebo (14) group. The CBD group received CBD-infused oil (2.5 mg/kg [1.1 mg/lb], PO) twice daily for 12 weeks in addition to existing antiepileptic treatments, and the placebo group received noninfused oil under the same conditions. ...
ANIMALS: 26 client-owned dogs with intractable idiopathic epilepsy. PROCEDURES: Dogs were randomly assigned to a CBD (n …
Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study.
Łebkowska-Wieruszewska B, Stefanelli F, Chericoni S, Owen H, Poapolathep A, Lisowski A, Giorgi M. Łebkowska-Wieruszewska B, et al. Res Vet Sci. 2019 Apr;123:26-28. doi: 10.1016/j.rvsc.2018.12.003. Epub 2018 Dec 17. Res Vet Sci. 2019. PMID: 30580232
The aim of this study was to explore the pharmacokinetics of the two main active compounds (THC and CBD) contained in the cannabis oil extract Bedrocan® in fasting and fed dogs. Bedrocan® (20% delta-9-tetrahydrocannabinol [THC] and 0.5% cannabidiol [CBD]) was administered at 1.5 and 0.037 mg/kg THC and CBD, respectively in fasted and fed dogs according to a 2 × 2 cross over study design. ...
The aim of this study was to explore the pharmacokinetics of the two main active compounds (THC and CBD) contained in the cannabis …
Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats.
Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Deabold KA, et al. Animals (Basel). 2019 Oct 19;9(10):832. doi: 10.3390/ani9100832. Animals (Basel). 2019. PMID: 31635105 Free PMC article.
The use of CBD-rich hemp products is becoming popular among pet owners with no long-term safety data related to consumption in adult dogs and cats. ...Cats do appear to absorb or eliminate CBD differently than dogs, showing lower serum concentrations and adverse effects of excessive licking and head-shaking during oil administration....
The use of CBD-rich hemp products is becoming popular among pet owners with no long-term safety data related to consumption in adult …
US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions.
Kogan L, Schoenfeld-Tacher R, Hellyer P, Rishniw M. Kogan L, et al. Front Vet Sci. 2019 Jan 10;5:338. doi: 10.3389/fvets.2018.00338. eCollection 2018. Front Vet Sci. 2019. PMID: 30687726 Free PMC article.
Recent veterinary graduates were less likely to recommend or prescribe CBD. The most commonly used CBD formulations were oil/extract and edibles. ...Recent graduates and those practicing in states with legalized recreational marijuana were more likely to agree that research regarding the use of CBD in dogs is needed. ...
Recent veterinary graduates were less likely to recommend or prescribe CBD. The most commonly used CBD formulations were oi
Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs.
Vaughn D, Kulpa J, Paulionis L. Vaughn D, et al. Front Vet Sci. 2020 Feb 11;7:51. doi: 10.3389/fvets.2020.00051. eCollection 2020. Front Vet Sci. 2020. PMID: 32118071 Free PMC article.
Objective: To determine the safety and tolerability of escalating doses of three cannabis oil formulations, containing predominantly CBD, THC, or CBD and THC (1.5:1) vs. placebo in dogs. ...Animals: Twenty healthy Beagle dogs (10 males, 10 females). Methods: Dogs were randomly assigned to one of five treatment groups (n = 4 dogs per group balanced by sex): CBD-predominant oil, THC-predominant oil, CBD/THC-predominant oil (1.5:1), sunflower oil placebo, medium-chain triglyceride oil placebo. ...
Objective: To determine the safety and tolerability of escalating doses of three cannabis oil formulations, containing predominantly …
Feedback